An osteogenic composition for implantation at or near a target tissue site beneath the skin is provided, the osteogenic composition comprising bone morphogenetic protein and a NEMO binding domain peptide, where the NEMO binding domain peptide reduces soft tissue inflammation at or near the target tissue site. In some embodiments, a method is provided for treating a target tissue site in a patient in need of such treatment, the method comprising implanting an osteogenic composition comprising bone morphogenetic protein and a NEMO binding domain peptide, where the NEMO binding domain peptide reduces soft tissue inflammation at or near the target tissue site.

The present invention pertains to novel bone graft substitute materials. These materials are porous, homogenously dispersed solid mixtures of calcium phosphate and pro-regenerative extracellular matrix (ECM)—and potentially any pharmaceutical agent and/or mineral—that have been infused with polydopamine. In some embodiments the bone graft materials have osteoinductive factors incorporated within them.

The present invention pertains to novel bone graft substitute materials. These materials are porous, homogenously dispersed solid mixtures of calcium phosphate and pro-regenerative extracellular matrix (ECM)—and potentially any pharmaceutical agent and/or mineral—that have been infused with polydopamine. In some embodiments the bone graft materials have osteoinductive factors incorporated within them.

The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug.

The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug.

The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.

The present application provides a method of making a particle comprising (i) obtaining a first solution comprising a negatively charged polysaccharide; (ii) obtaining a second solution comprising a positively charged polysaccharide; and (iii) mixing the first solution and the second solution to obtain a suspension comprising the particle. The present application also provides a method of making a therapeutic particle, comprising: (i) obtaining a solution comprising a therapeutic protein; (ii) obtaining a first suspension comprising the particle comprising a negatively charged polysaccharide and a positively charged polysaccharide, and (iii) mixing the solution of the therapeutic protein and the first suspension to obtain a second suspension comprising the therapeutic particle. The present application also provides particles (e.g., therapeutic particles) prepared by any one of the disclosed methods, as well as the compositions comprising such particles, and methods of treating a disease or condition using such particles and compositions.

Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions.

The present invention relates to a method for prevention or treatment of metabolic disease, administering a composition containing bone morphogenetic protein 10 (BMP10) as an active ingredient, in which brown fat differentiation was promoted in the cells of BMP10-treated mouse embryonic mesenchymal cell line C3H10T1/T2, increased browning effects of stromal vascular fraction adipose stem cells isolated from subcutaneous adipose tissue was confirmed, and weight loss, improved insulin resistance, and changes in blood lipid levels were confirmed in a high-fat-diet-induced obese animal model. Therefore, the composition containing BMP10 as an active ingredient can be provided as a drug for the prevention or treatment of metabolic diseases, including obesity, diabetes, and dyslipidemia.

The present disclosure provides devices comprising a therapeutic agent bound to a printed three-dimensional structure. The printed three-dimensional structure comprises about 50% to about 100% by weight ceramic and about 0% to about 50% by weight N polymer. Ink formulations for three-dimensional printing are also disclosed. Additionally, provided herein are methods for manufacturing devices and uses thereof, e.g., in treating a condition in a subject in need thereof.